Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Specimen Handling 200Magnetic Resonance Spectroscopy 151Biopsy 113Nivolumab 40Immunoglobulin G 40Disulfides 40Cisplatin 38Cyclophosphamide 37Platinum 36Paclitaxel 361,2-diaminocyclohexaneplatinum II citrate 36Carboplatin 35Taxes 34Radiation 34X-Rays 29Radiotherapy 28pembrolizumab 27Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 22Gemcitabine 22Vincristine 19Prednisone 19fludarabine 18Ipilimumab 18CTLA-4 Antigen 18venetoclax 17durvalumab 17Phantoms, Imaging 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Axitinib × 30 days × Clear all
NCT03595124 2026-06-15

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
15 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡